GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
Commentary|Slideshows|February 8, 2025
Clinical Pearls: Inside the Mind of the Athlete
With the Super Bowl highlighting elite athletic performance, sports psychiatry is essential in strengthening athletes' mental resilience and well-being.
Advertisement
Advertisement
Related to this article
A Delphi panel recommends screening for eating disorders before GLP-1 receptor agonist initiation.
GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.
GLP-1 drugs may quiet cravings by reshaping brain reward and satiety signals, reducing food-seeking drive and binge-like eating, while long-term effects remain unclear.
Ketamine or esketamine during C-section anesthesia lowers early postpartum depression symptom scores in trials, hinting at a new prevention approach under study.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Ozempic Dilemma: Promises and Pitfalls in Psychiatry
2
Schizophrenia: A Telltale of the Brain’s Complexity
3
Talking With Titans: Sheldon Preskorn, MD, on the Evolution of Psychopharmacology
4
Brain Trust: Bessel van der Kolk, MD, on Complex PTSD, Attachment, and the Limits of Pharmacotherapy
5